Stock Report

All about this stock under one free report Last Updated: 31-Aug-2026

Stock Rating

See the stock’s health at a glance, before it's too late.

Wealth Insight New Issue

Serious stock insights. No fluff. No FOMO.

Recently Viewed

Clear All

Laurus Labs Peer Comparison

Stock Card factsheet watchlist-stock-modal share-fund-plan-icon

NSE: LAURUSLABS | BSE: 540222

₹1,938.50

up-down-arrow ₹9.10 (0.47%)

As on 28-Aug-2026IST

Market cap

info icon

₹1,04,567 Cr

Revenue (TTM)

info icon

₹7,270 Cr

P/E Ratio

info icon

95.6

P/B Ratio

info icon

18.5

Div. Yield

info icon

0.1 %

Edit peer-selector-edit
Laurus Labs Glenmark Pharmaceuticals Wockhardt Rubicon Research Piramal Pharma
Market cap (₹ Cr)
 1,04,567 71,047 32,104 29,892 29,103
Revenue (₹ Cr)
 7,270 17,737 3,564 1,936 9,205
Net Profit (₹ Cr)
 1,090.76 1,797.81 414.00 288.22 -371.81
Net Margin (%)
 14.89 9.86 11.23 14.79 -3.93
RoE (%)
 21.64 30.87 8.38 29.77 -3.85
Price to Earnings
 95.64 39.52 78.49 103.71 --
Price-To-Book
 18.54 6.48 6.38 22.27 3.64

Income Statement (₹ Cr)

Laurus Labs Glenmark Pharmaceuticals Wockhardt Rubicon Research Piramal Pharma
Operating Revenue arrow
7,269.64 17,736.55 3,564.00 1,935.80 9,205.28
Total Income arrow
7,323.34 18,236.50 3,686.00 1,948.58 9,449.59
Total Expenditure arrow
5,235.79 12,939.86 2,792.00 1,485.56 8,195.15
EBITDA arrow
2,033.85 4,796.69 772.00 450.24 1,010.13
Depreciation arrow
487.08 616.73 226.00 50.83 857.51
EBIT arrow
1,546.77 4,179.96 546.00 399.41 152.62
Interest arrow
161.45 204.50 217.00 40.84 342.73
Other Income arrow
53.70 499.94 122.00 12.78 244.31
Exceptional Items arrow
0.00 -1,942.85 12.00 0.00 -216.88
Profit before Tax arrow
1,439.02 2,532.56 463.00 371.35 -162.68
Provision for Tax arrow
348.26 734.75 49.00 83.14 209.13
Profit after Tax arrow
1,090.76 1,797.81 414.00 288.22 -371.81

Liabilities (₹ Cr)

Laurus Labs Glenmark Pharmaceuticals Wockhardt Rubicon Research Piramal Pharma
Shareholder's Funds arrow
5,300.06 10,512.11 4,940.00 1,288.82 8,162.62
Minority Interest arrow
2.84 0.10 -5.00 0.00 0.00
Non-Current Liabilities arrow
1,444.40 3,019.66 1,712.00 202.03 5,044.14
Current Liabilities arrow
3,635.43 6,376.43 1,622.00 835.87 4,758.28
Total Liabilities arrow
10,511.19 19,906.65 8,578.00 2,326.71 17,723.32

Assets (₹ Cr)

Laurus Labs Glenmark Pharmaceuticals Wockhardt Rubicon Research Piramal Pharma
Non-Current Assets arrow
5,220.48 7,567.18 5,343.00 519.60 10,211.52
Current Assets arrow
4,829.21 11,299.71 2,606.00 1,681.81 7,191.66
Total Assets arrow
10,511.19 19,906.65 8,578.00 2,326.71 17,723.32
Total Debt* arrow
2,397.49 0.00 2,125.00 259.37 5,495.48
Net Current Assets arrow
1,193.78 4,923.28 984.00 845.94 2,433.38
Contingent Liabilities arrow
420.55 787.81 768.26 19.09 95.72

Cashflow (₹ Cr)

Laurus Labs Glenmark Pharmaceuticals Wockhardt Rubicon Research Piramal Pharma
Cash From Operating Activities arrow
1,623.50 3,445.03 390.00 205.05 1,652.60
Cash Flow from Investing Activities arrow
-1,088.66 -1,283.23 -241.00 -409.72 -826.03
Cash from Financing Activities arrow
-524.72 -2,708.75 -54.00 283.07 -38.98
Net Cash Inflow / Outflow arrow
10.12 -546.95 95.00 78.39 787.59

Ratios

Profitability Ratios

 Laurus Labs Glenmark Pharmaceuticals Wockhardt Rubicon Research Piramal Pharma
ROCE (%) arrow
18.20 20.35 6.79 29.22 1.24
ROE (%) arrow
21.64 30.87 8.38 29.77 -3.85
ROA (%) arrow
10.99 10.00 4.94 24.77 -2.21
EBIT Margin (%) arrow
21.28 23.57 15.32 20.63 1.66
Net Margin (%) arrow
14.89 9.86 11.23 14.79 -3.93
Cash Profit Margin (%) arrow
0.00 0.00 0.00 0.00 0.00

Growth Ratios

 Laurus Labs Glenmark Pharmaceuticals Wockhardt Rubicon Research Piramal Pharma
Revenue Growth (%) arrow
22.62 32.94 18.37 46.65 0.78
EBIT Growth (%) arrow
87.41 126.49 252.26 62.13 -70.53
Net Profit Growth (%) arrow
116.73 138.48 377.85 89.49 -1,383.43
EPS Growth (%) arrow
114.66 174.53 1,001.33 78.60 -484.84
Book Value Growth (%) arrow
18.63 18.53 13.47 144.31 0.33

Valuation Ratios

 Laurus Labs Glenmark Pharmaceuticals Wockhardt Rubicon Research Piramal Pharma
Price / Earnings arrow
95.58 22.91 80.56 102.12 -93.01
Price / Book Value arrow
18.54 6.48 6.38 22.27 3.64
Dividend Yield (%) arrow
0.10 0.10 0.00 0.08 0.00
EV/EBITDA arrow
52.54 14.57 43.48 66.20 32.91
Market Cap (₹ Cr) arrow
53,545.31 60,201.30 19,071.62 12,753.19 18,108.89

Solvency Ratios

 Laurus Labs Glenmark Pharmaceuticals Wockhardt Rubicon Research Piramal Pharma
Debt to Equity arrow
0.12 0.00 0.31 0.11 0.53
Short term debt to equity ratio arrow
0.28 -- 0.09 0.05 0.09
Current Ratio arrow
1.33 1.77 1.61 2.01 1.51
Quick Ratio arrow
0.68 1.23 1.06 1.14 0.87
Interest Coverage arrow
9.91 13.38 3.13 10.09 0.53

Operating Efficiency Ratios

 Laurus Labs Glenmark Pharmaceuticals Wockhardt Rubicon Research Piramal Pharma
Debtors to sales (%) arrow
29.64 27.98 16.50 26.28 23.44
Asset Turnover arrow
0.73 0.99 0.43 1.66 0.55
Receivable days arrow
111.49 43.78 58.75 40.13 78.20
Inventory Days arrow
114.62 34.05 75.82 60.29 93.30
Payable days arrow
155.13 264.58 186.21 232.47 226.14
Cash Conversion Cycle arrow
70.98 -186.74 -51.64 -132.04 -54.64
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
loading...
loading...
loading...
loading...
loading...